Correlation between change in C (panel A), T (panel B), C+T (panel C) and basal BMI (D) with Clinical Benefit (SD or PR as best response) during everolimus therapy.

<p>Correlation between change in C (panel A), T (panel B), C+T (panel C) and basal BMI (D) with Clinical Benefit (SD or PR as best response) during everolimus therapy.</p

Incidence of skeletal-related events (SREs) in patients with bone metastases from renal cell carcinoma (<i>N</i> = 398).

<p>Incidence of skeletal-related events (SREs) in patients with bone metastases from renal cell carcinoma (<i>N</i> = 398).</p

Skeletal-related events (SREs) are common in patients with bone metastasis from renal cell carcinoma (<i>N</i> = 398).

<p>Skeletal-related events (SREs) are common in patients with bone metastasis from renal cell carcinoma (<i>N</i> = 398).</p

Median Survival after Bone Metastases Diagnosis.

<p>SRE, skeletal-related event; ZOL, zoledronic acid.</p

Median time to first skeletal-related event (SRE) according to MSKCC risk score.

<p>MSKCC, Memorial Sloan-Kettering Cancer Center.</p

Baseline Patient Demographics.

<p>Baseline Patient Demographics.</p

Median time to first skeletal-related event (SRE) in renal cell carcinoma patients receiving ZOL (<i>n</i> = 181) and those who did not receive bisphosphonate treatment (<i>n</i> = 186).

<p>ZOL, zoledronic acid.</p

Median time to bone metastases diagnosis according to MSKCC risk score.

<p>^a Significant correlation between poor prognosis by MSKCC risk score and median time to bone metastasis (<i>P</i><0.05). MSKCC, Memorial Sloan-Kettering Cancer Center.</p